Table 1.
Correlation of IL-32 expression level with clinicopathological features in ESCC patients
| Variables | All cases (N) | IL-32 expression level (IHC-score) | P valuea, b | |
|---|---|---|---|---|
| Low, N (%) | High, N (%) | |||
| Age (year) | ||||
| < 57 | 15 | 9 (16.1) | 6 (10.7) | 0.905 |
| >=57 | 41 | 22 (39.3) | 19 (33.9) | |
| Gender | ||||
| Male | 41 | 24 (42.9) | 17 (30.4) | 0.626 |
| Female | 15 | 7 (12.5) | 8 (14.3) | |
| Tumor location | ||||
| Upper | 9 | 8 (14.3) | 1 (1.8) | 0.087 |
| Middle | 33 | 16 (28.6) | 17 (30.4) | |
| Lower | 14 | 7 (12.5) | 7 (12.5) | |
| Tumor differentiation | ||||
| Well | 10 | 8 (14.3) | 2 (3.6) | 0.159 |
| Moderate | 33 | 15 (26.8) | 18 (32.1) | |
| Poor | 13 | 7 (12.5) | 6 (10.7) | |
| Pathological stage | ||||
| IA-IB | 9 | 6 (10.7) | 3 (5.4) | 0.304 |
| IIA-IIB | 22 | 14 (25) | 8 (14.3) | |
| IIIA-IIIC | 25 | 11 (19.6) | 14 (25) | |
| Tumor stage | ||||
| T1-T2 | 24 | 13 (23.2) | 11 (19.6) | 0.265 |
| T3-T4 | 32 | 18 (32.1) | 14 (25) | |
| Nodal stage | ||||
| N0 | 27 | 18 (32.1) | 9 (16.1) | 0.025* |
| N1 | 21 | 12 (21.4) | 9 (16.1) | |
| N2-N3 | 8 | 1 (1.8) | 7 (12.5) | |
N Number
aχ2 test to compare clinicopathological parameters in IL-32 low-expression group versus high-expression group
bP < 0.05 is compared significant